GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bionomics Ltd (NAS:BNOX) » Definitions » LT-Debt-to-Total-Asset

Bionomics (Bionomics) LT-Debt-to-Total-Asset : 0.01 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bionomics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bionomics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.01.

Bionomics's long-term debt to total assets ratio increased from Sep. 2022 (0.00) to Dec. 2023 (0.01). It may suggest that Bionomics is progressively becoming more dependent on debt to grow their business.


Bionomics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Bionomics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionomics LT-Debt-to-Total-Asset Chart

Bionomics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.18 0.01 0.01 0.01

Bionomics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - 0.01 0.01

Bionomics LT-Debt-to-Total-Asset Calculation

Bionomics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )/Total Assets (A: Jun. 2023 )
=0.243/28.862
=0.01

Bionomics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0.182/26.006
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionomics  (NAS:BNOX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Bionomics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Bionomics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionomics (Bionomics) Business Description

Traded in Other Exchanges
Address
200 Greenhill Road, Eastwood, SA, AUS, 5063
Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.